ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 892

Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)

Nicolas Richard1, Nigil Haroon2, George Tomlinson3, Ismail Sari1, Zahi Touma4 and Robert D Inman1, 1Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), patient-reported outcome measures, quality of life and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects with axial spondyloarthritis (axSpA). Although this tool has previously been used in various research settings over the last decade, the minimal clinically important difference (MCID) remains to be defined.

Methods:

All subjects seen at the Spondylitis Clinic of the Toronto Western Hospital between July 2003 and January 2018 with a diagnosis of axSpA were included in this study. The ASQoL comprises 18 questions and answers are dichotomized into yes/no. The weighted score for each item is 1 and poorer HRQoL is associated with higher scores. The MCID for ASQoL was determined by anchor-based methods using two instruments to anchor the change on the ASQoL. The first anchor was the Health Transition Index (HTI) of the Short Form 36 (SF-36): “compared to one year ago, how would you rate your health in general now?”. The answers to this question at the yearly follow-up visit were incorporated in a 5-point Likert scale: “much worse” (-2), “somewhat worse” (-1), “about the same” (0), “somewhat better” (+1) or “much better” (+2). The second anchor was the change in the global self-rated health (GSRH) question of the SF-36 : “In general, would you say your health is […]”. The answers to this question are: “1- excellent”, “2- very good”, “3- good”, “4- fair” and “5- poor”. The level of change in GSRH between two consecutive visits was considered. A minimal change on the HTI was considered as anyone reporting better (+2 or +1) or worse (-2 or -1), and a minimal change on the GSRH was considered has those who had 1 level of improvement or worsening. The MCID for ASQoL was determined by plotting on receiver operating characteristic (ROC) curves the change in ASQoL that most accurately classified subjects based on optimal sensitivity/specificity ratio (improvement or worsening).

Results:

The study consisted of a total of 1328 subjects with longitudinal data cumulated over 5607 visits. Based on ROC curve analyses (image), the MCID for improvement is -2: this had a sensitivity of 40% and specificity of 84% anchored on the HTI, and sensitivity of 43% and specificity of 79% anchored on the GSRH. The MCID for worsening is 1, having a sensitivity/specificity of 40%/84% anchored on the HTI and 43%/79% anchored on the GSRH. Larger cut-off values for ASQoL resulted in a linear increase in the positive predictive value (PPV) up to thresholds of -5 for improvement (PPV=71% anchored on the HTI and PPV=55% anchored on the GSRH) and 5 for worsening (PPV=57% anchored on the HTI and PPV=53% anchored on the GSRH).

Conclusion:

This study gives values for MCID and further suggests that larger threshold values in ASQoL change may be applied to better classify subjects according to improvement or worsening in HRQoL. Defining cut-off values will enhance the utility of ASQoL in clinical and research settings.


Disclosure: N. Richard, None; N. Haroon, None; G. Tomlinson, None; I. Sari, None; Z. Touma, None; R. D. Inman, None.

To cite this abstract in AMA style:

Richard N, Haroon N, Tomlinson G, Sari I, Touma Z, Inman RD. Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/establishing-the-minimal-clinically-important-difference-mcid-for-the-ankylosing-spondylitis-quality-of-life-questionnaire-asqol/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/establishing-the-minimal-clinically-important-difference-mcid-for-the-ankylosing-spondylitis-quality-of-life-questionnaire-asqol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology